Jane Street
LOGC

Jane Street’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Jane Street’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-51,381
Closed -$18K – 10828
2022
Q2 		$18K Buy
+51,381
New +$26K ﹤0.01% 9200
2021
Q3 		– Sell
-12,748
Closed -$57K – 11092
2021
Q2 		$57K Buy
+12,748
New +$64.9K ﹤0.01% 9477

Other funds holding LOGC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Jane Street's LOGC Position: Q3 2022 in Review

Jane Street sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q3 2022, closing a stake of 51,381 shares — an estimated $18K sold.

Jane Street first reported a position in LOGC in Q2 2021 and held it in 2 quarters. The position peaked at $57K in Q2 2021. 39 funds tracked by Wall St. Rank hold LOGC as of Q3 2022.

  • Jane Street reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Jane Street sold 51,381 LogicBio Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $18K.
  • Jane Street first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • Jane Street's LogicBio Therapeutics, Inc. Common Stock position peaked at $57K in Q2 2021.
  • 39 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Jane Street's 13F filing for Q3 2022, filed 15 Nov 2022.